RVMD’s Near-100% Year-To-Date Rally Sparks Valuation Debate: Has the Stock Gotten Too Pricy? Jun 5, 2026 Life Science
Strong Demand for GLP-1 Drugs Drives Eli Lilly’s Leadership with New Oral Medication and Acquisitions Jun 4, 2026 Life Science
Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities Jun 4, 2026 Life Science
Gene Editing Could Become the Next “Golden Rush” in the Pharmaceutical Industry, What Does This Mean for CRISPR Therapeutics? Jun 3, 2026 Life Science
Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge Jun 3, 2026 Life Science
AbbVie Faces a Challenger in Johnson & Johnson, but Investors Need Not Panic Jun 3, 2026 Life Science
Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath Jun 2, 2026 Life Science
5 Institutional-Approved High-Dividend Pharmaceutical Stocks for Passive Income Investors May 29, 2026 Life Science
Riding on Strong Earnings and a $1.5 Billion Market Catalyst, Exelixis Is Poised for Takeoff May 28, 2026 Life Science
Is It Wise to Follow the Herd and Buy the Same Weight-Loss Drug Giant as the U.S. President? May 28, 2026 Life Science
Billionaires Reduce Holdings in UnitedHealth, Yet Wall Street Remains Bullish May 28, 2026 Life Science
